|
[1]CHEN QB,PENG AP,LI CC,et al.Suppressive effects of bezafibrate on proliferation and lytokine production by CD4+T tells from patients with primary biliary cirrhosis[J].Chin J Immunol,2014,30(10):1388-1392.(in Chinese)陈曲波,彭桉平,黎翠翠,等.苯扎贝特对原发性胆汁性肝硬化患者外周血CD4+T细胞的抑制作用研究[J].中国免疫学杂志,2014,30(10):1388-1392.
|
|
[2]KUMAGI T,HEATHCOTE EJ.Primary biliary cirrhosis[J].Nihon Naika Gakkai Zasshi,2008,3(5):1.
|
|
[3]ZHOU XY,TIAN YZ.The recent advances in the treatment of refractory primary biliary cirrhosis[J].Jilin J Tradit Chin Med,2014,34(11):1185-1188.(in Chinese)周新源,田耀州.难治性原发性胆汁性肝硬化治疗进展[J].吉林中医药,2014,34(11):1185-1188.
|
|
[4]CORPECHOT C,CHRETIEN Y,CHAZOUILLERES O,et al.Demographic,lifestyle,medical and familial factors associated with primary biliary cirrhosis[J].J Hepatol,2010,53(1):162-169.
|
|
[5]SILVEIRA MG,BRUNT EM,HEATHCOTE EJ,et al.American Association for the Study of Liver Diseases endpoints conference:design and endpoints for clinical trials in primary biliary cirrhosis[J].Hepatology,2010,52(1):349-359.
|
|
[6]POUPON R.Primary biliary cirrhosis:a 2010 update[J].J Hepatol,2010,52(5):745-758.
|
|
[7]LINDOR KD,GERSHWIN ME,POUPON R,et al.Primary biliary cirrhosis[J].Hepatology,2009,50(1):291-308.
|
|
[8]JIANG DQ,LU Y,SHEN G,et al.One case of serum AMA-M2 negative primary biliary cirrhosis[J/CD].Chin J Liver Dis:Electronic E-dition,2015,7(3):149-150.(in Chinese)蒋德强,路遥,申戈,等.血清AMA-M2阴性原发性胆汁性肝硬化1例[J/CD].中国肝脏病杂志:电子版,2015,7(3):149-150.
|
|
[9]MENDES F,LINDOR KD.Antimitochondrial antibody-negative primary biliary cirrhosis[J].Gastroenterol Clin North Am,2008,37(2):479-484.
|
|
[10]GUO YP,WANG CG,LIU X,et al.Evaluation of markers associated with primary biliary cirrhosis in a population of anti-mitochondrial antibody-M2-positive individuals[J].Chin J Hepatol,2014,22(10):735-738.(in Chinese)郭亚平,王春光,刘欣,等.抗线粒体抗体-M2阳性体检人群原发性胆汁性肝硬化相关指标的调查分析[J].中华肝脏病杂志,2014,22(10):735-738.
|
|
[11]MURATORI L,GRANITO A,MURATORI P,et al.Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis:diagnostic and prognostic value[J].Clin Liver Dis,2008,12(2):261-276.
|
|
[12]QIN X,YU J.Results analysis and clinical application of auto‐antibodies detection in primary biliary cirrhosis[J].Lab Med Clin,2015,1(4):484-485.(in Chinese)秦霞,余俊.原发性胆汁性肝硬化自身抗体检测结果分析及临床应用[J].检验医学与临床,2015,1(4):484-485.
|
|
[13]HU CJ,ZHANG FC,LI YZ,et al.Primary biliary cirrhosis:what do autoantibodies tell us?[J].World J Gastroenterol,2010,16(29):3616-3629.
|
|
[14]NAKAMURA M,KONDO H,MORI T,et al.Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis[J].Hepatology,2007,45(1):118-127.
|
|
[15]CZAJA AJ.The overlap syndromes of autoimmune hepatitis[J].Dig Dis Sci,2013,58(2):326-343.
|
|
[16]TALWALKAR JA.Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis[J].Liver Int,2008,28(6):761-763.
|
|
[17]CORPECHOT C,El NAGGAR A,POUJOL-ROBERT A,et al.Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC[J].Hepatology,2006,43(5):1118-1124.
|
|
[18]FLOREANI A,FRANCESCHET I,CAZZAGON N,et al.Extrahepatic autoimmune conditions associated with primary biliary cirrhosis[J].Clin Rev Allergy Immunol,2015,48(2-3):192-197.
|
|
[19]TADA F,ABE M,NUNOI H,et al.Ulcerative colitis complicated with primary biliary cirrhosis[J].Intern Med,2011,50(20):2323-2327.
|
|
[20]KUMAGI T,GUINDI M,FISCHER SE,et al.Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis[J].Am J Gastroenterol,2010,105(10):2186-2194.
|
|
[21]AZEMOTO N,ABE M,MURATA Y,et al.Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis[J].J Gastroenterol,2009,44(6):630-634.
|
|
[22]AZEMOTO N,KUMAGI T,ABE M,et al.Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis[J].Hepatol Res,2011,41(4):310-317.
|
|
[23]CORPECHOT C,CARRAT F,BAHR A,et al.The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis[J].Gastroenterology,2005,128(2):297-303.
|
|
[24]WANG L,GUO GY,WANG JB,et al.A decline of LAMP-2predicts ursodeoxycholic acid response in primary biliary cirrhosis[J].Sci Rep,2015,20(5):9772.
|
|
[25]NGUYEN DL,JURAN BD,LAZARIDIS KN.Primary biliary cirrhosis[J].Best Pract Res Clin Gastroenterol,2010,24(5):647-654.
|
|
[26]POUPON R.Evidence-based treatment of primary biliary cirrhosis[J].Dig Dis,2014,32(5):626-630.
|
|
[27]ZHANG H,YANG J,ZHU R,et al.Combination therapy of ursodeoxycholic acid and budesonide for PBC-AIH overlap syndrome:a meta-analysis[J].Drug Des Devel Ther,2015,17(9):567-574.
|
|
[28]KAPLAN MM,BONDER A,RUTHAZER R,et al.Methotrexate in patients with primary biliary cirrhosis who respond incompletely to treatment with ursodeoxycholic acid[J].Dig Dis Sci,2010,55(11):3207-3217.
|
|
[29]HOSONUMA K,SATO K,YAMAZAKII Y,et al.A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia[J].Am J Gastroenterol,2015,110(3):423-431.
|
|
[30]GRIGORIAN AY,MARDINI HE,CORPECHOT C,et al.Fenofibrate is effective adjunctive therapy in the treatment of primary biliary cirrhosis:a meta-analysis[J].Clin Res Hepatol Gastroenterol,2015,39:296-306.
|
|
[31]TSUDA M,MORITOKI Y,LIAN ZX,et al.Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid[J].Hepatology,2012,55(2):512-521.
|
|
[32]HIRSCHFIELD GM,MASON A,LUKETIC V,et al.Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid[J].Gastroenterology,2015,148(4):751-761.
|
|
[33]SCHREUDER TC,HUBSCHER SG,NEUBERGER J.Autoimmune liver diseases and recurrence after orthotopic liver transplantation:what have we learned so far?[J].Transpl Int,2009,22(2):144-152.
|
DownLoad: